STOCK TITAN

CORCEPT THERAPEUTICS (CORT) SEC Filings, Sep 2-15, 2026

CORT NASDAQ

Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.

The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.

Rhea-AI Summary

Corcept Therapeutics Inc. (CORT) insider James N. Wilson filed a Rule 144 notice indicating an intention to sell up to 30,000 shares of common stock, to be sold through The Charles Schwab Corporation, with an aggregate market value of $3,344,400. The shares relate to stock option awards dated February 24, 2026. Wilson also reported prior sales of 10,000 shares for $882,986 on July 15, 2026 and 10,000 shares for $1,114,261 on August 14, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
other
-
Rhea-AI Summary

CORCEPT THERAPEUTICS INC (CORT) received a Rule 144 notice from officer Joseph Douglas Lyon regarding a planned sale of company stock. The notice reports an intended sale of 10,000 shares of common stock, to be issued through a stock option exercise for cash on September 14, 2026, with sales through broker Stifel Nicolaus on NASDAQ.

The filing also reports that over the prior three months, Joseph D. Lyon sold 1,540 shares of common stock on August 3, 2026. Rule 144 requires this disclosure of planned and recent sales by affiliates of the issuer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
other
-
Rhea-AI Summary

CORCEPT THERAPEUTICS INC (CORT) reported that Chief Development Officer William Guyer acquired common stock on September 1, 2026 through company equity programs. He purchased 164 shares under a purchase plan established under the 2024 Incentive Award Plan at $113.38 per share, based on that day's closing price, and received an additional 164 shares as unvested restricted stock awards that will vest in full one year after grant if he remains the beneficial owner of the purchase-plan shares and meets plan requirements. Separate unvested restricted stock awards granted on December 1, 2025, March 2, 2026 and June 1, 2026 also remain outstanding and vest on their respective one-year anniversaries subject to conditions. No Rule 10b5-1 trading plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
insider
Rhea-AI Summary

CORCEPT THERAPEUTICS INC (CORT) reported that officer Sean Maduck exercised options for 25,000 shares of common stock on September 1, 2026 at an exercise price of $8.27 per share, then sold 25,000 shares the same day in multiple trades around $114–$116 per share under a Rule 10b5-1 trading plan. He also had 117 shares of common stock withheld on September 2, 2026 to cover tax obligations related to vesting restricted stock units and acquired small additional amounts of stock through a purchase plan and restricted stock awards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
insider
-
Rhea-AI Summary

CORCEPT THERAPEUTICS INC (CORT) reported that its Chief Financial Officer, Atabak Mokari, had routine equity-related transactions. On September 1, 2026, he acquired 138 shares of common stock under a purchase plan at a price based on the closing price that day and also received 138 shares underlying unvested restricted stock awards that will vest after one year if he remains the beneficial owner of the purchase-plan shares. On September 2, 2026, 102 shares of common stock were withheld to satisfy tax withholding obligations related to the vesting of restricted stock units; no Rule 10b5-1 trading plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
insider
-
Rhea-AI Summary

CORCEPT THERAPEUTICS INC (CORT) reported insider equity activity by Chief Business Officer Gary Charles Robb. On September 1, 2026, he acquired 164 shares of common stock through a purchase plan and a further 164 shares underlying restricted stock awards, which vest after one year if specified conditions are met. On September 2, 2026, 91 shares were withheld by the company to satisfy tax withholding obligations upon vesting of restricted stock units. He also reports indirect ownership of 39,716 shares held in a revocable trust, plus additional shares in custodial accounts for his children.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
insider
Rhea-AI Summary

CORCEPT THERAPEUTICS INC (CORT) reported that President, Oncology Roberto Wandenkolk Vieira exercised stock options for 58,333 shares of common stock at $21.63 per share on September 2, 2026, then sold 58,333 shares in multiple open-market transactions and had 102 shares withheld to satisfy tax obligations. These sales were made under a Rule 10b5-1 trading plan adopted on June 17, 2026. On September 1, 2026 he also acquired 138 shares through a purchase plan and 138 restricted shares that vest after one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
insider
-
Rhea-AI Summary

CORCEPT THERAPEUTICS INC (CORT) reported that Chief Accounting & Technology Officer Joseph Douglas Lyon had several equity compensation-related transactions. On September 1, 2026, he acquired 130 shares of common stock under a purchase plan at $113.38 per share and received an additional 130 shares of restricted stock awards that carry a one-year cliff vesting condition tied to continued beneficial ownership of the purchase-plan shares. On September 2, 2026, 72 shares of common stock were withheld by the company at a price based on the September 1 closing price of $113.38 to satisfy tax withholding obligations from vesting restricted stock units; no Rule 10b5-1 trading plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
insider
-
Rhea-AI Summary

CORCEPT THERAPEUTICS INC (CORT) reports the initial equity holdings of Roberto Wandenkolk Vieira, who serves as President, Oncology. He directly holds 4,068 shares of Common Stock, including unvested restricted stock awards, and three option grants to purchase up to 480,000 shares of Common Stock at exercise prices of $21.63, $60.58 and $35.70 with expirations in 2034, 2035 and 2036.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
insider
Rhea-AI Summary

CORCEPT THERAPEUTICS INC (CORT) has a notice of proposed sale under Rule 144 for up to 75,295 shares of common stock for the account of officer Roberto Wandenkolk Vieira, to be sold through Stifel Nicolaus & Company Inc. The shares include 74,999 acquired through a stock option exercise on February 1, 2024 and 296 acquired through an ESPP purchase on September 1, 2026. The notice cites an aggregate market value of $8,339,418 and 108,098,397 shares of common stock outstanding, with an approximate sale date of September 2, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
other

FAQ

How many CORCEPT THERAPEUTICS (CORT) SEC filings are available on StockTitan?

StockTitan tracks 201 SEC filings for CORCEPT THERAPEUTICS (CORT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for CORCEPT THERAPEUTICS (CORT)?

The most recent SEC filing for CORCEPT THERAPEUTICS (CORT) was filed on November 13, 2026.